Nasdaq:STTK

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

June 05, 2026 16:05 ET | Source: Shattuck Labs, Inc. AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE)…

3 hours ago